Showing results (911-920 of 993) with videos related to
Sort By:
Pageof 100
British Journal of Cancer|June 2, 2005
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinomaJ J Ord, E Streeter, A Jones, et al.British Journal of Cancer|October 28, 2005
A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivityT Kato, R Prevo, G Steers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effectsD J Propper, M P Saunders, A J Salisbury, et al.British Journal of Cancer|August 28, 2003
A phase 1 study of tazarotene in adults with advanced cancerP H Jones, R D Burnett, I Fainaru, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000D J Propper, J de Bono, A Saleem, et al.Childhood Obesity (Print)|April 20, 2022
Parents as Agents of Change in Managing Pediatric Obesity: A Randomized Controlled Trial Comparing Cognitive Behavioral Therapy versus Psychoeducation InterventionsNicholas D Spence, Amanda S Newton, Rachel A Keaschuk, et al.Oncogene|October 6, 2015
PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancerS-J Fan, C Snell, H Turley, et al.European Journal of Cancer & Clinical Oncology|January 1, 1983
Aminoglutethimide for the treatment of advanced postmenopausal breast cancerA L Harris, T J Powles, I E Smith, et al.Oncogene|August 30, 2016
Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4U Harjes, E Bridges, K M Gharpure, et al.Lung Cancer (Amsterdam, Netherlands)|November 27, 2001
Towards a biological staging model for operable non-small cell lung cancerK J O'Byrne, G Cox, D Swinson, et al.Pageof 100